System and method for use for linking primary market research data ...

67
l|||||||||||||ll||l||||||||l|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| US 20030061096A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0061096 A1 Gallivan et al. (43) Pub. Date: Mar. 27, 2003 (54) sYsTEM AND METHOD FOR UsE FOR Publication Classi?cation LINKING PRIMARY MARKET RESEARCH DATA WITH SECONDARY RESEARCH DATA (51) Int. c1.7 ................................................... .. G06F 17/60 (52) us. Cl. ................................................. .. 705/14; 705/2 (76) Inventors: Gerald J. Gallivan, Naples, FL (US); Timothy A. Margraf, Medford, NJ (US); Lorie M. Preston, NeWtoWn, PA (57) ABSTRACT (US); Gerhard K. Gallwitz, Haddon?eld, NJ (US) A computerized system and method for conducting a survey COIIfISPOHdGHCfI AddreSSI of the promotional activities of sales representatives for CAESAR, RIVISE, BERNSTEIN, speci?c pharmaceuticals of the various pharmaceutical com COHEN & POKOTILOW, LTD- panies. A single panel of physicians is provided to collect 12TH FLOOR’ SEVEN PENN CENTER data regarding both (1) the promotional activities of the sales 1635 MARKET STREET representatives Whom they have encountered, and (2) the PHILADELPHIA, PA 19103-2212 (US) diagnosis and treatment of their patients. The data is pro _ vided into a database for analysis to evaluate any cause and (21) Appl' NO" 10/142,028 effect relationship betWeen the promotional activities of the (22) Filed: May 9, 2002 sales representatives and the pharmaceuticals prescribed by them to their patients. Primary market research studies can Related US, Application Data also be conducted by select appropriate physicians from the panel to Whom a survey is to be administered and by (63) Continuation-in-part of application No. 09/947,034, analyzing their ansWers in the context of the data in the ?led on Sep. 5, 2001. database. I Internet Client Communication 3 Protocol (ICCP API) 26 / 28 30 E _ 4O \ Staging Transformation System 22 and Staging Transformation 4 System Metadata U/ZII-N --_u>\ 2‘ "a 22 . Other Transactlon Data Model (Raw Data) <— negrence ata 46 i \ Warehouse Decislon Support System (DSS) Table Generation 52 48 ¢ )0 Data Warehouse cDh;ri‘:‘i:\i/|:,::e/‘ SQL Server : V (Dimenslonyvarehouse) : > Cusmmlza‘ion Summanzed Data P ararneters ll Riggs; Client Data F213;?! Extracts Tools

Transcript of System and method for use for linking primary market research data ...

l|||||||||||||ll||l||||||||l|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| US 20030061096A1

(19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0061096 A1

Gallivan et al. (43) Pub. Date: Mar. 27, 2003

(54) sYsTEM AND METHOD FOR UsE FOR Publication Classi?cation LINKING PRIMARY MARKET RESEARCH DATA WITH SECONDARY RESEARCH DATA (51) Int. c1.7 ................................................... .. G06F 17/60

(52) us. Cl. ................................................. .. 705/14; 705/2 (76) Inventors: Gerald J. Gallivan, Naples, FL (US);

Timothy A. Margraf, Medford, NJ (US); Lorie M. Preston, NeWtoWn, PA (57) ABSTRACT (US); Gerhard K. Gallwitz, Haddon?eld, NJ (US)

A computerized system and method for conducting a survey COIIfISPOHdGHCfI AddreSSI of the promotional activities of sales representatives for CAESAR, RIVISE, BERNSTEIN, speci?c pharmaceuticals of the various pharmaceutical com COHEN & POKOTILOW, LTD- panies. A single panel of physicians is provided to collect 12TH FLOOR’ SEVEN PENN CENTER data regarding both (1) the promotional activities of the sales 1635 MARKET STREET representatives Whom they have encountered, and (2) the PHILADELPHIA, PA 19103-2212 (US) diagnosis and treatment of their patients. The data is pro

_ vided into a database for analysis to evaluate any cause and (21) Appl' NO" 10/142,028 effect relationship betWeen the promotional activities of the (22) Filed: May 9, 2002 sales representatives and the pharmaceuticals prescribed by

them to their patients. Primary market research studies can Related US, Application Data also be conducted by select appropriate physicians from the

panel to Whom a survey is to be administered and by (63) Continuation-in-part of application No. 09/947,034, analyzing their ansWers in the context of the data in the

?led on Sep. 5, 2001. database.

I

Internet Client Communication

3 Protocol (ICCP API)

26 / 28 30

E

_ 4O

\ Staging Transformation System 22 and Staging Transformation 4

System Metadata

U/ZII-N --_u>\ ‘

2‘ "a 22 . Other Transactlon Data Model

(Raw Data) <— negrence ata

46 i \ Warehouse Decislon Support

System (DSS) Table Generation

52 48 ¢ )0 Data Warehouse cDh;ri‘:‘i:\i/|:,::e/‘

SQL Server : V (Dimenslonyvarehouse) : > Cusmmlza‘ion Summanzed Data P

ararneters

ll

Riggs; Client Data F213;?! Extracts Tools

Patent Application Publication Mar. 27, 2003 Sheet 1 0f 43 US 2003/0061096 A1

by :‘t 22-1 ,

P Internet Client Communication El

- \‘ > 5 Protocol

(ICCP API)

26 / 28 30

2/2_N 20 D

l +

\ Staging Transformation System 22 and Staging Transformation <——

System Metadata

[g] 24-N ‘ 24 44 42

\ - Other / Transactlon Data Model (Raw Data) 4- Regarence

I ata

Hg. 1 l 46

\ Warehouse Decision Support System (DSS) Table Generation

52 48 $ 50

Data Warehouse cglg?xsrzgit SQL Server <—-> (Dtmenslon warehouse) <—> Customization

Summarized Data Parameters

Front End Cllent Data Access Extracts

Tools

54 ' \ 56 58

Patent Application Publication Mar. 27, 2003 Sheet 4 of 43 US 2003/0061096 A1

Fig. 4 I Pharmaceutical Representative Tracking Form 0 Fax form daily to 888-XXX-XXXX I

Pharmaceutical representatives requesting to see Dr. Date; please pm“ Clearly 0 Did the representative get beyond the front desk I waiting room? . which company provided lunch? ' Enter today‘s date to the right

- Fill in the square in the appropriate column. I Correct EH! Incorrect 1: :I l l a n u 1' 0 [Office Staff First, Last Name] Call at 800-XXX~XXXX with any questions. M M D D

1“ Rep 2"‘l Rep Lunch 1“ Rep 2"1 Rep Lunch Company Y“ No Yes N0 Provided Company Yes No Yes No Provided

Abbott U U U U U Organon U U U / U U Allen & Hanburys U U U U U Ortho-McNeil U U U U U

Alla U U U U U PDI U U U U U Astra U U U U U P?zer Labs U U U U U AstraZeneca U U U U U Pharmacia U U U U U Aventis U U U U U Pratt U U U U U Bayer U U U U U Proct & Gamble U U U U U Beecham Labs U U U U Purdue Frederick U U U U U Bristol-Myers Squibb U U U U U Reliant U U U U U Boehringer lng. U U U U U Roche U U U U U Burroughs Wellcm U U U U U Roerig U U U U U Centocor U U U U U Ross Labs U U U U U Cerenex U U U U U Sandoz U U U U U Dura U U U U U Sankyo U U U U U Elan U U U U U Sanofi U U U U U

Fforest 74> _m U U U U U Schering U U U U U

GlaxoSmithKline U U U U U Schwarz U U U U U HitchingS U U U U U Searle U U U iUiw U Hoechst M.R. El El [:1 ‘it El Samarium it? "13 t1 [1 U Janssen U U U U U SmithKline U U U U U Key Pharma U U U U U Solvay U U U U U Knoll Pharma U U U U U Takeda U U U U U

Lederle U U U U U TAP U U U U U Lifecycle U U U U U UCB Pharma U U U U U Lilly U U U U U Upjohn U U U U U McNeil U U U U U Wallace U U U U U

Merck U r U U U U Watson U U U U U

Monarch U U U U U V Whitehall Robins U U U i U

Novartis U U U U U Wyeth-Ayerst U U U U U Novo Nordisk U U U U U Zeneca U U U U U

U NO REPS VISITED Write in Company Names Below If Not Found Above:

U OFFICE CLOSED g g [1 5 U U DOCl" OR OUT OF OFFICE (All reps visiting D U U D U of?ce MUST be recorded) U U U U U

I I] l] E B 0 0 Z 7 B 7 l: I

Patent Application Publication Mar. 27, 2003 Sheet 5 0f 43 US 2003/0061096 A1

Sales Rep Visits

Meetings and Events

‘Product Detail 1 Product FILLEGRH? Discussion Type. M Compared To: 2(LHRITINE isual “iii 7 paper [I No trade-off between power & non El Nanirnpairlng while drlving [I Nansedating even at 2x recommen

‘Sales Rep Visit

" I3 Gen Prd Disc I] None afHbove Pmdu‘t Dem“ Message otation ail-Detail‘ T’ Of?ce [ Edit Message 1 [ Done )(ccmtel J The Sales Rep stated that Filieg‘ra was a

great praduci, but did not mention retommended dosage‘

Product: EFiLLEGRH-Di

Na Prd Discussed

ime Spent with Rep: 7 > NJ min

Detail I-HLLEGRFI Detail Z-FiLLEGFiFi-D Product Detail 3

Product Discussion

two way

‘ 'ZHOURF Compared To. ZN Visual ?ld: v paper [I] Slg. rellefat Just 45 min. compared

: [i Smooih dist pseudophedrine-entir _ @@f [1 Powerful decangeshon even at ira

I [I For patients i2yr

F | g . 6 E! Gen Prd Disc [II None of?bove Edit Message [ Done (ancei

Patent Application Publication Mar. 27, 2003 Sheet 6 0f 43 US 2003/0061096 A1

Meeting or EventUlZ) Meeting or Event (Z/Z) Meeting/Event Do i 800/01? Speaker: Dr. Smith Sponsor: TopicMonogemel-n hypertensiod Speaker Info: v Local specialist

I Topic Quality: v 6 attendee (ount: I0

I Location: v Restaurant I Lotution Quohty: v Very Good

13 (ME (reditsoffereld

Product. (i Noxure‘ v prod (speci?c Program Length: v 1-2 hours

@QED(@

Fig. 8 DHy Impact Network - Version: ‘2.0.0

Fih "Took... Holy , "

\?silDake: Age, Handel, Haas: Inswance: , Location~

[401 IESSENTIAL HYPEFITENSIIJN i] Diagnosis Type

I Q] Paiientvisis

F NewlyDiagnosed F Mnd piM?deiale [7 Die! [-7 Résl I'- Alternative I7 PievD' ->-- F Seven [7 Exercisé I'- Ulhe'r'

r Did Paiienl Request Dlug By Name?

may‘); F Drug Requested [comm _1_] i

nx1~viagnosis1 [5112 I ma] Product Name. Form/Shengh '

ILIPITDH _§] poms TABLET i] , I" R" ' Dispensed I20 Scl'ieduia' BID i Re?lls: '3

' U'i'engejn Diué fiéotinerii lY/Nl Change Type: ‘Switched to a new Medication ' I

Piocbol Switch: » I ' ’ ‘ Plevious Product you; lzocon 3]

Why Switched: lno! achleving dashed LDL and HDL levels in plasma

Patent Application Publication Mar. 27, 2003 Sheet 7 0f 43 US 2003/0061096 A1

and Proposal Development With Client I / ’ 202 I/ 204 200

Research Provider ~

sixeienmg I Query Transaction Data Criteria and —- > Model = Quota Setting I

Client |

44 214 I

/I Research Instrument Development I 210/ I Develop Research ‘ | Secondary Reseeirch Transaction Data

' Instrument ‘ (e.g., Internet, Pink Model

212/,.|/ ‘ | Sheets, etc.) I It It

218_,_I___,———# Conduct Pretest |

: I Existing Research 216 Modify | <e-g-- @9351;

I Research response 8 , .)

Instrument \ 222 l v |\ Prepare 4I T 220

Survey I | Selected Network /228 _ _ — — w A ' — — — —' _' Physicians

Field Survey <__—J —> (e.g., On-line, telephone, mail, in person, \—

etc.)

224 226

r

. Query Transaction Data ‘ Analysls Of Survey Resullts Model ‘

I /23o Integrated Analysis

I / /232 l _ _ _ _ — — — — — — — _ —" “ —/— w I

Output Report(s) I

Client Perceptual Map Other Oualitative/ Report(s) Quantitative Report(s)

Patent Application Publication Mar. 27, 2003 Sheet 9 0f 43 US 2003/0061096 A1

<: .3 \bmbwbk $2536 922 12:23.65“ iotgnmwm 25 251515

Patent Application Publication Mar. 27, 2003 Sheet 11 0f 43 US 2003/0061096 A1

AS2603

6:0 0: 8.32:8 258:8 2: MQSQEQ: 1 200m 2225 32%3 2: m2: :mcEo: 2 :2: 222:8 2: o: 6320 65:05 2: coEmom 8 :03 EB ??woa @552: 2: £25258 :22/8 5:5 8860mm“ Emmi 2 8363 m b 28% Ec2w5€::-o>>: E RENEE:

$0522: 2522 2a 832:8 E0: @2282: 2: 65E E :82 8 220: $59

022582: $22223“: 2: 50: 3:2338

:2: E 38:86 53 m5 8 :5: d2: 2.: no 5:528: E 320 2m :2: 82603 6m?N 8260i 2:0 8 :2368 2558 5:223 :2: so 262: 2: :0 5:283“

2: 2:2: 2: dEnEE SN 9 2 65:9: @ :2: 51522: E M220 2: “32: 2: :O

33: “2:95.25 .wBBEE

:0 :3 m :5“ $00.50 5253 8:22am“ 2: so :38 92: E5322: 2: @238 2 3:32: 052::02 :EoEwomEoo m an 8 :22228 2 29228 moqwgommobou .32: $5382: 2: 28.6 o: :8: £3 wibmc< oucowucomwubonv

“$28328: 9.5222 b 32200522 >

0S .5

Patent Application Publication Mar. 27, 2003 Sheet 12 0f 43 US 2003/0061096 A1

mm~$>oo ho Eatuwnw umEmi. mEmoa 22:02.69

93k 2 in? 2:95 $5220... @000.

a: .5

EPZwEODE 395m, $2300 28 ummmcwz noon

03.3231 2 $5935? 2:025 .89 63 u zv 2352a 58 mmcsmm 2:254. E32 - 052225

Patent Application Publication Mar. 27, 2003 Sheet 17 0f 43 US 2003/0061096 A1

.33? “8:55

@3555 .E\ @595“ ??wmem @QEE 8 062 £2.35» MS“ \a 39% SN,“

.8553 35

H8 A? we 30 m hocnhm?m?q won m8 Q Hon Ho 5L (5 :6 b Ho 8 6.6% was m m8 m BBSHQ 6 @BE >2: $62?» no n33 wQEQEwQw 82> 256555

92605 32: H8 $528 85588

so 8mg :82? 2 80:33 How 2E? EVENE “233w Mo 8C3 38: 2t 5

22m “aims- b wcozhmohwn “2.62m b mmEuc: B 59555 >

E .5

US 2003/0061096 A1

o2": yam m?az HmHuc Hxom mat

xcm monk “o2 ....... .. mom morn 3am

amqs 19)].IBW

Patent Application Publication Mar. 27, 2003 Sheet 18 0f 43

NQEQEHMN .5.“ 53% a a E mmwcg?outu ~80

22m 3152 xmEoEgN b , . @ wwmcm>zowtm “moo > H

_J_\ r mmEuzE um=£m0 F